Oncology Final Exam with all Correct & 100% Verified
Answers |Already Graded A+
Name therapeutic agent to treat EGFR mutation biomarker in nonsmall-cell lung cancer.Hint: 3
major ones. ✔Correct Answer-1. Gefitinib
2. Erlotinib
3. Afatinib
Name therapeutic agent to treat ALK positive biomarker(EML4-ALK rearrangement) for NSCLC
OR ROS1 biomarker. ✔Correct Answer-Crizotinib
Name therapeutic agents to treat BRAF positive biomarker for NSCLC. ✔Correct Answer-
Vemurafenib and dabraenib
HER2 overexpression is associated with better or worse prognosis for breast cancer?
✔Correct Answer-Worse prognosis.
HER-2 testing includes ____________ and ______________(name two tests). These tests
detect__________. HER2 positive breast cancer may be treated with _______________.
✔Correct Answer-1. FISH and IHC(immunohistochemistry)
2. HER 2 protein overexpression and gene amplification from the tumor
3. Trastuzumab
HER2 is evaluated at these two times in a breast cancer patient's course of therapy. ✔Correct
Answer-Diagnosis or recurrence.
Oncotoype Dx Test- explain the test, how it's scored, when it's indicated. ✔Correct Answer-1.
A 21 gene expression test(not genotype) on breast tumor tissue. Expression is measured from
multiple genes involving cancer cell proliferation, invasion, estrogen, and HER2 genes.
2. Measured from 0-100 on recurrence score obtained from expression test performed on
tumor. This number corresponds to likelihood of recurrence w/in 10 yrs.
3. Use in newly diagnosed ER +, Node - or +, HER-2 negative breast cancer
What is considered low risk, Intermediate risk, or high risk RS oncotype dx score? What therapy
for each risk category to recommend in ER/PR+ breast cancer? ✔Correct Answer-Low= 0-18%,
little to no chemo benefit(most women fall in this category). Recommend only tamoxifen.
Intermediate= 18-31%, may be a chemo benefit. May or may not use combo adjuvant chemo
followed by tamoxifen.
High= 31% and above, Large chemo benefit. Combination adjuvant chemo followed by
tamoxifen.
Answers |Already Graded A+
Name therapeutic agent to treat EGFR mutation biomarker in nonsmall-cell lung cancer.Hint: 3
major ones. ✔Correct Answer-1. Gefitinib
2. Erlotinib
3. Afatinib
Name therapeutic agent to treat ALK positive biomarker(EML4-ALK rearrangement) for NSCLC
OR ROS1 biomarker. ✔Correct Answer-Crizotinib
Name therapeutic agents to treat BRAF positive biomarker for NSCLC. ✔Correct Answer-
Vemurafenib and dabraenib
HER2 overexpression is associated with better or worse prognosis for breast cancer?
✔Correct Answer-Worse prognosis.
HER-2 testing includes ____________ and ______________(name two tests). These tests
detect__________. HER2 positive breast cancer may be treated with _______________.
✔Correct Answer-1. FISH and IHC(immunohistochemistry)
2. HER 2 protein overexpression and gene amplification from the tumor
3. Trastuzumab
HER2 is evaluated at these two times in a breast cancer patient's course of therapy. ✔Correct
Answer-Diagnosis or recurrence.
Oncotoype Dx Test- explain the test, how it's scored, when it's indicated. ✔Correct Answer-1.
A 21 gene expression test(not genotype) on breast tumor tissue. Expression is measured from
multiple genes involving cancer cell proliferation, invasion, estrogen, and HER2 genes.
2. Measured from 0-100 on recurrence score obtained from expression test performed on
tumor. This number corresponds to likelihood of recurrence w/in 10 yrs.
3. Use in newly diagnosed ER +, Node - or +, HER-2 negative breast cancer
What is considered low risk, Intermediate risk, or high risk RS oncotype dx score? What therapy
for each risk category to recommend in ER/PR+ breast cancer? ✔Correct Answer-Low= 0-18%,
little to no chemo benefit(most women fall in this category). Recommend only tamoxifen.
Intermediate= 18-31%, may be a chemo benefit. May or may not use combo adjuvant chemo
followed by tamoxifen.
High= 31% and above, Large chemo benefit. Combination adjuvant chemo followed by
tamoxifen.
